Radioligand therapy with lutetium-177-PSMA in metastatic castration-resistant prostate cancer with bone involvement: a comprehensive review
Pharmateca · 13.07.2026 · 4_2026 · 216-221
DOI: 10.18565/pharmateca.2026.4.216-221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmateca, erschienen am 13.07.2026. Verfasst von Khakimov G.A. Khakimov und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Khakimov, K. G., Nasirkhodzhaev, N. Y., Khakimova, K. G., Sobitov, S. S., & Erkinova, E. S. (2026). Radioligand therapy with lutetium-177-PSMA in metastatic castration-resistant prostate cancer with bone involvement: a comprehensive review. Pharmateca, 4_2026, 216-221. https://doi.org/10.18565/pharmateca.2026.4.216-221
Vancouver
Khakimov KG, Nasirkhodzhaev NY, Khakimova KG, Sobitov SS, Erkinova ES. Radioligand therapy with lutetium-177-PSMA in metastatic castration-resistant prostate cancer with bone involvement: a comprehensive review. Pharmateca. 2026;4_2026:216-221. doi:10.18565/pharmateca.2026.4.216-221
BibTeX
@article{Khakimov2026,
author = {Khakimov, Khakimov G.A. and Nasirkhodzhaev, Nasirkhodzhaev Ya.B. and Khakimova, Khakimova G.G. and Sobitov, Sobitov S.A. and Erkinova, Erkinova Sh.I.},
title = {Radioligand therapy with lutetium-177-PSMA in metastatic castration-resistant prostate cancer with bone involvement: a comprehensive review},
journal = {Pharmateca},
year = {2026},
volume = {4_2026},
pages = {216--221},
doi = {10.18565/pharmateca.2026.4.216-221}
}
EUVIMED